Navigation Links
DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results

ndpoints, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and DURECT's (and that of its third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to its development activities and products, or ability to design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced product candidates, manufacture and commercialize the referenced product candidates, obtain marketplace acceptance of the referenced product candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund its growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q on November 4, 2010 under the heading "Risk Factors."

DURECT CORPORATION STATEMENTS OF OPERATIONS DATA(in thousands, except per share amounts)(unaudited)Three months ended Year ended December 31, December 31, 201020092010 2009  (1)Collaborative research and development and other revenue

$  5,929$  2,802$  20,091$  12,347Product revenue, net

2,5672,07611,50012,113Total revenues

8,4964,87831,59124,460Operating expenses:Cost of revenues (2)

1,1778164,2755,311Research and development (2)

9,4479,26736,21434,801Selling, general and administrative (2)

4,0453,43214,93715,020Total operating expenses

14,66913,51555,42655,132Loss from operations

(6,173)(8,637)(23,835)(30,672)Other income (expense):Interest and other income

85853943420Interest and other expense

(1)(5)(6)(36)Net other income

85748937384Net loss

$ (5,316)$ (8,589)$ (22,898)$ (30,288)Net loss per share, basic and diluted

$   (0.06)$   (0.10)$
(0.36)Shares used in computing basic and diluted net los

Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
2. DURECT Corporation Announces Third Quarter 2008 Financial Results
3. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
7. Genaera Corporation Announces Second Quarter Financial Results
8. MannKind Corporation Reports Second Quarter Financial Results
9. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
10. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Post Your Comments:
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
(Date:7/10/2014)... to the International Atomic Energy Agency (IAEA) the ... acquiring sufficient quantities of plutonium or highly enriched ... device. The IAEA also notes that most cases ... which can be challenging to detect with most ... appearing this week in the Journal of ...
(Date:7/10/2014)... psychiatric disorders has been extremely challenging because there are ... insufficient to cause disease. Now investigators reporting in the ... Cell Stem Cell describe a strategy that may ... other risk factors or environmental exposures to affect the ... genetic variant that may predispose individuals to schizophrenia. ...
(Date:7/10/2014)... for crude 3-D glasses, polarized glasses, and shutter ... devices, used to trick the brain into perceiving ... obsolete with the introduction of new holography technology ... doctoral students Yuval Yifat, Michal Eitan, and Zeev ... nanoantennas that could be used for security as ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... November 2007, BARCELONA, Spain, October 9 ... 332 patients,with Overactive Bladder (OAB) and has been ... Spain, The Netherlands, Czech Republic, Hungary,Poland, Russia, South ... report the results of this trial during November. ...
... PARI Respiratory Equipment,s,breath-enhanced nebulizer, the PARI LC ... new COPD medication, Perforomist Inhalation Solution,that launched ... of Mylan Inc.,(NYSE: MYL ). ... for,long-term, twice-daily maintenance treatment of bronchoconstriction for,emphysema ...
... Solution, to Orthopedic Imaging, PARIS and ATLANTA, Oct. ... 510k clearance from the Food and Drug Administration,(FDA) to ... United States for 2D,imaging use. EOS 2D|3D technology ... images to be obtained with a low dose of ...
Cached Biology Technology:SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder 2PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 2PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 3PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 4FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 2FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 3FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 4
(Date:7/11/2014)... explored two different ways that allow unprecedented experimental ... formation of oxygen molecules in photosynthesis. The two ... Nature Communications . , "The new knowledge ... water oxidation, which are key components for building ... solar energy in fuels like hydrogen, ethanol or ...
(Date:7/11/2014)... that transplantation of mesenchymal stem cells can stimulate neurogenesis ... of Alzheimer,s disease (AD) and improve tissue and function ... are reported on the therapeutic effect of adipose-derived stem ... the effect on oxidative injury and neurogenesis in the ... team, School of Life Sciences, Tsinghua University, China transplanted ...
(Date:7/11/2014)... 1 can inhibit voltage-gated calcium channel, decrease ... However, some scholars demonstrated that cannabinoid receptor ... and increase neurotransmitter release. Dr. Yi Zhang ... Tongji Medical College, Huazhong University of Science ... and calcium imaging in cultured trigeminal ganglion ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... Jan. 26, 2012  Medbox, Inc. (Pinksheets: MDBX) ( ... products for 2012. Through their ... medicine dispensing and storage systems, which are designed ... centers, alternative medicine clinics and doctor,s offices. The ...
... cause serious damage along the shoreline, but they also cause significant ... of extreme coastal storms in the Western Mediterranean published in the ... The researchers, led by Anna Sanchez-Vidal of the University ... the most extreme storm in the area over the last 25 ...
... 25, 2012  ChromaDex Corporation (OTCBB: CDXC), an innovative ... and ingredients to the dietary supplement, food & ... its BluScience ( ) line ... McKesson to approximately 4,000 independent drugstores and pharmacies. ...
Cached Biology News:Medbox, Inc. Announces New Product Line for 2012 2ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 2ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 3ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 4
... stem cells (HSC) are well-characterized tissue-specific stem ... are responsible for the life-long maintenance of ... that reside in adult bone marrow where ... also be found in cord blood, fetal ...
... Atrophin 1 ( Abpromise for all ... Synthetic peptide conjugated to KLH derived from ... Human Atrophin 1.(Note: the amino acid sequence ... Entrez GeneID: 1822 ...
NNT-1/BSF-3 (N-14)...
This antibody detects an ~92 kDa protein corresponding to the apparent molecular mass of the beta subunit of Hypoxia Inducible Factor-1 (HIF-1beta) on Western blots....
Biology Products: